Ischemic Heart Disease (IHD) Drugs Global Market Report 2024

Description

Ischemic heart disease (IHD) drugs refer to medications employed in the management and treatment of a condition characterized by reduced blood flow to the heart muscle, often due to narrowing of the coronary arteries. These drugs aim to alleviate symptoms, reduce the risk of complications such as heart attacks, and improve overall cardiac function.

The primary drug classes encompassed by ischemic heart disease (IHD) drugs include anti-dyslipidemic drugs, calcium channel blockers, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), vasodilators, and antithrombotic agents. Anti-dyslipidemic drugs are pharmacological agents targeting and reducing abnormal lipid levels (such as cholesterol and triglycerides) in the bloodstream to mitigate the risk of cardiovascular disease. These drugs are utilized in the treatment of various conditions, including angina pectoris and myocardial infarction, and are distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies.

The ischemic heart disease (IHD) drugs market research report is one of a series of new reports from The Business Research Company that provides ischemic heart disease (IHD) drugs market statistics, including ischemic heart disease (IHD) drugs industry global market size, regional shares, competitors with a ischemic heart disease (IHD) drugs market share, detailed ischemic heart disease (IHD) drugs market segments, market trends and opportunities, and any further data you may need to thrive in the ischemic heart disease (IHD) drugs industry. This ischemic heart disease (IHD) drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ischemic heart disease (ihd) drugs market size has grown strongly in recent years. It will grow from $6.02 billion in 2023 to $6.36 billion in 2024 at a compound annual growth rate (CAGR) of 5.7%. The growth observed in the historical period can be attributed to several factors, including the rising global prevalence of ischemic heart disease, increased awareness and diagnostics, changes in lifestyle and dietary patterns, government initiatives promoting cardiovascular health, collaborations for clinical trials, and favorable insurance coverage and reimbursement policies.

The ischemic heart disease (ihd) drugs market size is expected to see steady growth in the next few years. It will grow to $7.57 billion in 2028 at a compound annual growth rate (CAGR) of 4.4%. The anticipated growth in the forecast period can be attributed to trends such as aging population patterns, the adoption of personalized medicine approaches, an increased emphasis on cardiovascular prevention, global health policies, and international research collaborations. Major trends expected in the forecast period include a shift towards precision medicine approaches, a focus on novel anti-atherogenic agents, advancements in lipid-lowering therapies, the integration of anti-inflammatory agents, and the development of antithrombotic and antiplatelet drugs.

The growth in the prevalence of obesity and diabetes is expected to drive the expansion of the ischemic heart disease (IHD) drugs market. Diabetes, a chronic metabolic disease characterized by elevated blood glucose levels, and obesity, a condition marked by excess body fat accumulation, pose significant health risks. Ischemic heart disease drugs are commonly prescribed for individuals with obesity and diabetes to manage cardiovascular risk factors such as hypertension and dyslipidemia, thereby mitigating the risk of ischemic heart disease. For example, the World Obesity Federation reported in March 2023 that obesity rates are expected to double among boys and more than double among girls by 2035. The projected increase in the number of people with obesity is estimated to reach 2.7 billion by 2025. Additionally, the International Diabetes Federation noted in December 2021 that diabetes affected 537 million adults in 2021, with predictions of reaching 643 million by 2030 and 783 million by 2045. Consequently, the growing prevalence of obesity and diabetes serves as a key driver for the growth of the ischemic heart disease (IHD) drugs market.

The increasing incidence of heart failure is another factor expected to contribute to the growth of the ischemic heart disease (IHD) drug market. Heart failure, a chronic condition where the heart muscle cannot pump enough blood, often leads to symptoms such as fatigue and shortness of breath. Ischemic heart disease drugs play a crucial role in treating heart failure by reducing risk factors and symptoms associated with IHD. These medications can be particularly beneficial for heart failure patients with reduced ejection fractions and high resting heart rates. For instance, data from the Heart Failure Society of America in September 2023 indicates that 6.7 million Americans over 20 years of age have heart failure, and this prevalence is expected to increase to 8.5 million Americans by 2030. The rising incidence of heart failure is a key driver for the growth of the ischemic heart disease (IHD) drug market.

The high cost of treatment is poised to be a potential restraint for the ischemic heart disease (IHD) drugs market in the future, as it may impede access to care for patients facing financial constraints. The elevated cost of IHD treatment can result in delayed diagnosis and treatment, heightening the risk of complications and adversely affecting the sales of IHD drugs. Affordability challenges may make it difficult for patients to access the necessary care, leading to potential financial hardships. For instance, data published by GoodRx Health in August 2022 highlighted heart disease as one of the most expensive health conditions to treat in the US. Even with insurance, out-of-pocket expenses for a heart condition often exceed $2,000 per year. Atherosclerosis, contributing to thickening or hardening of the arteries, can lead adults under 65 to incur annual out-of-pocket medical expenses exceeding $2,000, in addition to insurance premiums. Patients with heart failure may face annual out-of-pocket expenses reaching $5,000. Consequently, the high cost of treatment stands as a significant barrier to growth in the ischemic heart disease (IHD) drugs market.

Major companies operating in the ischemic heart disease (IHD) drugs market are intensifying their focus on developing innovative platelet inhibitors, including intravenous P2Y12 platelet inhibitors, to gain a competitive advantage. Intravenous P2Y12 platelet inhibitors are medications administered directly into the bloodstream to prevent platelet activation and aggregation, reducing the risk of periprocedural myocardial infarction (MI), a type of ischemic heart disease. For example, MSN Laboratories Private Limited, an India-based research-based pharmaceutical company, launched CANREAL injection (Cangrelor) in October 2021. This intravenous P2Y12 platelet inhibitor is recognized for its rapid onset and offset of platelet inhibition, addressing both delayed and prolonged antiplatelet activity. It serves as a bioequivalent generic drug indicated as an adjunct to percutaneous coronary intervention to reduce the risk of myocardial infarction (MI).

In August 2021, Philip Morris International Inc., a US-based tobacco company, acquired OtiTopic Inc. for an undisclosed amount. This acquisition reflects Philip Morris International's strategic move to expand its portfolio of 'beyond nicotine' products and enhance its pipeline of inhaled therapeutic products. OtiTopic Inc., a US-based manufacturer, focuses on respiratory drugs for myocardial infarction (MI), a specific type of ischemic heart disease.

Major companies operating in the ischemic heart disease (ihd) drugs market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Sandoz Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd., Cipla Limited, Lupin Limited, Recordati S.p.A., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alembic Pharmaceuticals Ltd., Eagle Pharmaceuticals Inc., Accord Healthcare Limited, Macleods Pharmaceuticals Ltd., WG Critical Care LLC, Novitium Pharma LLC.

North America was the largest region in the ischemic heart disease (IHD) drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ischemic heart disease (ihd) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the ischemic heart disease (IHD) drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The ischemic heart disease (IHD) drugs market consists of sales of antiarrhythmic drugs, anticoagulants, anti-anginal medications, nitroglycerin and nitrates, statins, and antiplatelet agents. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Ischemic Heart Disease (IHD) Drugs Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on ischemic heart disease (ihd) drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for ischemic heart disease (ihd) drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The ischemic heart disease (ihd) drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

1) By Drug Class: Anti-Dyslipidemic Drugs; Calcium Channel Blockers; Beta-Blockers; Angiotensin-converting enzyme (ACE) Inhibitors; Angiotensin II Receptor Blockers (ARBs); Vasodilators; Antithrombotic Agents
2) By Disease Class: Angina Pectoris; Myocardial Infarction
3) By End User: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.; Bayer AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r16263

1. Executive Summary

2. Ischemic Heart Disease (IHD) Drugs Market Characteristics

3. Ischemic Heart Disease (IHD) Drugs Market Trends And Strategies

4. Ischemic Heart Disease (IHD) Drugs Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Ischemic Heart Disease (IHD) Drugs Market Size and Growth

5.1. Global Ischemic Heart Disease (IHD) Drugs Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Ischemic Heart Disease (IHD) Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Ischemic Heart Disease (IHD) Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Ischemic Heart Disease (IHD) Drugs Market Segmentation

6.1. Global Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Anti-Dyslipidemic Drugs
Calcium Channel Blockers
Beta-Blockers
Angiotensin-converting enzyme (ACE) Inhibitors
Angiotensin II Receptor Blockers (ARBs)
Vasodilators
Antithrombotic Agents
6.2. Global Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Angina Pectoris
Myocardial Infarction
6.3. Global Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

7. Ischemic Heart Disease (IHD) Drugs Market Regional And Country Analysis

7.1. Global Ischemic Heart Disease (IHD) Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Ischemic Heart Disease (IHD) Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Ischemic Heart Disease (IHD) Drugs Market

8.1. Asia-Pacific Ischemic Heart Disease (IHD) Drugs Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Ischemic Heart Disease (IHD) Drugs Market

9.1. China Ischemic Heart Disease (IHD) Drugs Market Overview
9.2. China Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Ischemic Heart Disease (IHD) Drugs Market

10.1. India Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Ischemic Heart Disease (IHD) Drugs Market

11.1. Japan Ischemic Heart Disease (IHD) Drugs Market Overview
11.2. Japan Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Ischemic Heart Disease (IHD) Drugs Market

12.1. Australia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Ischemic Heart Disease (IHD) Drugs Market

13.1. Indonesia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Ischemic Heart Disease (IHD) Drugs Market

14.1. South Korea Ischemic Heart Disease (IHD) Drugs Market Overview
14.2. South Korea Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Ischemic Heart Disease (IHD) Drugs Market

15.1. Western Europe Ischemic Heart Disease (IHD) Drugs Market Overview
15.2. Western Europe Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Ischemic Heart Disease (IHD) Drugs Market

16.1. UK Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Ischemic Heart Disease (IHD) Drugs Market

17.1. Germany Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Ischemic Heart Disease (IHD) Drugs Market

18.1. France Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Ischemic Heart Disease (IHD) Drugs Market

19.1. Italy Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Ischemic Heart Disease (IHD) Drugs Market

20.1. Spain Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Ischemic Heart Disease (IHD) Drugs Market

21.1. Eastern Europe Ischemic Heart Disease (IHD) Drugs Market Overview
21.2. Eastern Europe Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Ischemic Heart Disease (IHD) Drugs Market

22.1. Russia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Ischemic Heart Disease (IHD) Drugs Market

23.1. North America Ischemic Heart Disease (IHD) Drugs Market Overview
23.2. North America Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Ischemic Heart Disease (IHD) Drugs Market

24.1. USA Ischemic Heart Disease (IHD) Drugs Market Overview
24.2. USA Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Ischemic Heart Disease (IHD) Drugs Market

25.1. Canada Ischemic Heart Disease (IHD) Drugs Market Overview
25.2. Canada Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Ischemic Heart Disease (IHD) Drugs Market

26.1. South America Ischemic Heart Disease (IHD) Drugs Market Overview
26.2. South America Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Ischemic Heart Disease (IHD) Drugs Market

27.1. Brazil Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Ischemic Heart Disease (IHD) Drugs Market

28.1. Middle East Ischemic Heart Disease (IHD) Drugs Market Overview
28.2. Middle East Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Ischemic Heart Disease (IHD) Drugs Market

29.1. Africa Ischemic Heart Disease (IHD) Drugs Market Overview
29.2. Africa Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Ischemic Heart Disease (IHD) Drugs Market Competitive Landscape And Company Profiles

30.1. Ischemic Heart Disease (IHD) Drugs Market Competitive Landscape
30.2. Ischemic Heart Disease (IHD) Drugs Market Company Profiles
- 30.2.1. Pfizer Inc.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. F. Hoffmann-La Roche Ltd.
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Merck & Co. Inc.
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. AbbVie Inc.
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Bayer AG
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Ischemic Heart Disease (IHD) Drugs Market Other Major And Innovative Companies

31.1. Novartis AG
31.2. Sanofi S.A.
31.3. Bristol-Myers Squibb Company
31.4. AstraZeneca PLC
31.5. GSK PLC
31.6. Eli Lilly and Company
31.7. Boehringer Ingelheim International GmbH
31.8. Viatris Inc.
31.9. Baxter International Inc.
31.10. Teva Pharmaceutical Industries Ltd.
31.11. Sandoz Inc.
31.12. Sun Pharmaceutical Industries Limited
31.13. Dr. Reddy's Laboratories Ltd.
31.14. Cipla Limited
31.15. Lupin Limited

32. Global Ischemic Heart Disease (IHD) Drugs Market Competitive Benchmarking

33. Global Ischemic Heart Disease (IHD) Drugs Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Ischemic Heart Disease (IHD) Drugs Market

35. Ischemic Heart Disease (IHD) Drugs Market Future Outlook and Potential Analysis

35.1 Ischemic Heart Disease (IHD) Drugs Market In 2028 - Countries Offering Most New Opportunities
35.2 Ischemic Heart Disease (IHD) Drugs Market In 2028 - Segments Offering Most New Opportunities
35.3 Ischemic Heart Disease (IHD) Drugs Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer